- This event has passed.
May 18, 2021 @ 1:00 pm - 2:00 pm
The more you know about funding, the more successful you’re going to be. Funding your early-stage life science startup is a challenging task. And the rules have changed in the past year! Adaptation is critical and learning how to virtually connect to the right investors is paramount. Join our panel of experts and VC’s to learn about new funds and financing trends, mistakes to avoid leading up to financing, and everything you need to know about a term sheet. Sharpen your pencils for part 1 of funding fundamentals.
James Huie, Partner, Wilson Sonsini Goodrich & Rosati
James Huie is a corporate and securities partner in Wilson Sonsini Goodrich & Rosati’s San Francisco office. James advises life sciences and technology companies on general corporate matters, mergers and acquisitions, initial public offerings, strategic partnerships, and private equity and debt financings. He also has extensive experience in representing venture capital firms and other investors in private equity and debt financings.
Marc Lajoie, PhD, CEO, Outpace Bio
Marc Lajoie completed his PhD in George Church’s lab at Harvard University, where he developed genome scale engineering and synthesis technologies, created the first genomically recoded organism with a reassigned genetic code, and co-founded GRO Biosciences. He co-founded Lyell Immunopharma, where he led a group developing new technologies to improve T cell therapies before spinning this team out as an independent company, Outpace Bio, which uses protein design to create mechanism-driven solutions that dramatically improve efficacy and safety of cell and gene therapies. Marc was named 30 under 30 in science by Forbes Magazine in 2012.
Peter Thompson, MD, Partner, OrbiMed Healthcare Fund Management
Peter Thompson, MD, is a Partner on the private equity team, with over 25 years of industry experience. He held executive positions at Becton-Dickinson and Chiron, co-founded and was CEO of Trubion Pharmaceuticals, co-founded Corvus Pharmaceuticals, Cleave Biosciences, Silverback Therapeutics and serves as a Director on several company boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.
Jon Edwards, PhD, Managing Director, Red Tree Venture Capital
Dr. Edwards is Managing Director at Red Tree Venture Capital and part of the founding investment team. Prior to joining Red Tree, he helped launch Medicxi (a therapeutics focused venture fund) where he was most recently a partner in the London office. Jon began his venture capital career at Index Ventures in Switzerland. Before moving to Europe, Jon was a life sciences strategy consultant at ClearView Healthcare Partners based in Boston. Jon’s investments include Synthorx (acquired by Sanofi), Phathom Pharmaceuticals (NASDAQ:PHAT), Checkmate Pharmaceuticals (NASDAQ:CMPI), Impact Biomedicines (acquired by Celgene), Sydnexis Inc., Xenikos B.V., and Breakpoint Therapeutics Gmbh.